Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to advance its lead multiple sclerosis (MS) candidate, Lucid-MS, into Phase 2 clinical development. The FDA approved the company's Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the initiation of a randomized, double-blind, placebo-controlled study to evaluate the drug's efficacy, safety, and tolerability in people with MS.
The upcoming Phase 2 trial will use both clinical and radiological measures to assess the treatment's impact. Quantum BioPharma has begun trial start-up activities, including site selection, and aims to begin patient enrollment and drug administration as quickly as possible.
Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, the process that damages the protective myelin sheath around nerve fibers in MS. This mechanism differentiates it from existing MS therapies, which primarily focus on modulating the immune system. The candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown.
Prior Phase 1 trials in healthy participants showed that Lucid-MS had a favorable safety profile and was well tolerated. The company also reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may support the advancement of the program.
The approval of the IND application is a significant milestone for Quantum BioPharma and for the MS community. If successful in Phase 2, Lucid-MS could offer a new therapeutic approach that directly addresses the underlying neurodegenerative process of MS, potentially slowing or reversing disability progression. This contrasts with current treatments that mainly reduce inflammation but may not fully prevent long-term nerve damage.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is dedicated to advancing Lucid-MS, which is a patented new chemical entity. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets an over-the-counter version of its alcohol misuse product, and is entitled to royalty payments from Unbuzzd sales.
The FDA's clearance brings hope to patients and healthcare providers for a potential disease-modifying therapy that could alter the course of MS. According to the National Multiple Sclerosis Society, nearly 1 million people in the United States live with MS, and there is an unmet need for treatments that can repair or protect myelin. If Lucid-MS proves effective in later-stage trials, it could become a valuable addition to the MS treatment landscape.
For more information on the press release, visit https://ibn.fm/HyWYH. To stay updated on Quantum BioPharma's news, see https://ibn.fm/QNTM.
